Anti-Aspergillus fumigatus IgG in patients with bronchiectasis and its relationship with clinical outcome.
Arch Microbiol
; 204(12): 728, 2022 Nov 24.
Article
en En
| MEDLINE
| ID: mdl-36434134
ABSTRACT
Aspergillosis is a mycosis, most commonly affecting the airways. This mycosis can worsen the clinical condition of patients with concurrent lung diseases. We assayed for the presence of serum anti-A. fumigatus IgG in bronchiectasis patients from a tertiary hospital in south Brazil and evaluated the relationship with clinical outcome. Thirty-one patients with bronchiectasis, without cystic fibrosis, were included. Clinical and epidemiological data were collected from all participants. Positive serological tests were detected in 13% (4/31) of the patients. The mortality rate for the year following the assay was, in the seropositive group, 75% (3/4), whereas in the seronegative group, 15% (4/27). An illustrative case is also shown and discussed. Our study highlights the diagnostic challenge and the possible impact of Aspergillus infection on these patients, indicating the necessity of more and larger investigations in the field.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aspergilosis
/
Bronquiectasia
/
Fibrosis Quística
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Arch Microbiol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Brasil